Brii Biosciences Limited (HK:2137)
:2137
Want to see HK:2137 full AI Analyst Report?
2137 Stock Chart & Stats
HK$1.44
HK$0.04(3.74%)
At close: 4:00 PM EST
HK$1.44
HK$0.04(3.74%)
Day’s Range― - ―
52-Week RangeHK$1.28 - HK$2.54
Previous CloseN/A
Volume2.92M
Average Volume (3M)6.36M
Market Cap
HK$967.22M
Enterprise ValueHK$239.21M
Total Cash (Recent Filing)HK$1.94B
Total Debt (Recent Filing)HK$8.93M
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding734,530,500
10 Day Avg. Volume5,897,564
30 Day Avg. Volume6,360,478
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)0.38
Price to Sales (P/S)50.44
P/FCF Ratio-3.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.21
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Sizable EquityVery low leverage and multi-year positive equity provide durable financial flexibility. This cushion reduces refinancing risk, supports ongoing R&D and commercialization investments, and gives management runway to execute strategy without immediate solvency pressure over the next 2–6 months.
Reduced Cash Burn In 2025A year-over-year reduction in cash burn signals improving cash efficiency and cost control. While cash flow remains negative, the trend reduces near-term external funding pressure and extends operational runway, making execution of late-stage commercialization and milestones more sustainable.
Partnering-driven Commercial ModelA diversified revenue model — product sales plus licensing, royalties and milestone payments — spreads development and commercialization risk. Structural partnerships can accelerate market access, outsource costs, and generate non-linear milestone upside independent of internal sales scale.
Bears Say
Persistent Negative Cash FlowConsistent negative operating and free cash flow means the business requires ongoing funding to sustain operations. Over months, this increases dependence on external capital, can dilute shareholders, and constrains investment in commercialization or pipeline expansion absent durable cash generation.
Ongoing Loss-making And Revenue ContractionPersistent net losses and a material revenue decline in 2025 versus 2024 indicate the company has not achieved scale or margin stability. This undermines the path to self-sustaining profitability and raises execution risk for commercialization initiatives over the medium term.
Dependence On Partner Performance And MilestonesHeavy reliance on partner-driven milestones and approvals creates structural revenue timing risk. Delays or underperformance by collaborators can materially defer license income and royalties, making cash flow and growth volatile and limiting company control over commercialization outcomes.
Brii Biosciences Limited News
2137 FAQ
What was Brii Biosciences Limited’s price range in the past 12 months?
Brii Biosciences Limited lowest stock price was HK$1.28 and its highest was HK$2.54 in the past 12 months.
What is Brii Biosciences Limited’s market cap?
Brii Biosciences Limited’s market cap is HK$967.22M.
When is Brii Biosciences Limited’s upcoming earnings report date?
Brii Biosciences Limited’s upcoming earnings report date is Aug 20, 2026 which is in 103 days.
How were Brii Biosciences Limited’s earnings last quarter?
Brii Biosciences Limited released its earnings results on Mar 19, 2026. The company reported -HK$0.034 earnings per share for the quarter, beating the consensus estimate of -HK$0.069 by HK$0.034.
Is Brii Biosciences Limited overvalued?
According to Wall Street analysts Brii Biosciences Limited’s price is currently Overvalued.
Does Brii Biosciences Limited pay dividends?
Brii Biosciences Limited does not currently pay dividends.
What is Brii Biosciences Limited’s EPS estimate?
Brii Biosciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Brii Biosciences Limited have?
Brii Biosciences Limited has 734,530,500 shares outstanding.
What happened to Brii Biosciences Limited’s price movement after its last earnings report?
Brii Biosciences Limited reported an EPS of -HK$0.034 in its last earnings report, beating expectations of -HK$0.069. Following the earnings report the stock price went down -3.947%.
Which hedge fund is a major shareholder of Brii Biosciences Limited?
Currently, no hedge funds are holding shares in HK:2137
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Brii Biosciences Limited
Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19. It also develops BRII-296 for the treatment of PPD; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for the treatment of MDR/XDR tuberculosis and non-tuberculosis mycobacteria. The company was incorporated in 2017 and is based in Beijing, China.
Technical Analysis
Genor Biopharma Holdings Limited
―
3D Medicines, Inc.
―
TOT BIOPHARM International Co. Ltd.
―
JW (Cayman) Therapeutics Co. Ltd.
―
Hightide Therapeutics Inc
―
Options Prices
Currently, No data available
---